- Home
- OLO vs COGT Comparison
OLO vs COGT Comparison
Compare OLO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- COGT
- Stock Information
- Founded
- OLO 2005
- COGT 2014
- Country
- OLO United States
- COGT United States
- Employees
- OLO N/A
- COGT N/A
- Industry
- OLO Major Banks
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- COGT Health Care
- Exchange
- OLO Nasdaq
- COGT Nasdaq
- Market Cap
- OLO 1.0B
- COGT 1.1B
- IPO Year
- OLO 2021
- COGT 2018
- Fundamental
- Price
- OLO $10.48
- COGT $11.42
- Analyst Decision
- OLO Buy
- COGT Strong Buy
- Analyst Count
- OLO 3
- COGT 9
- Target Price
- OLO $10.17
- COGT $20.25
- AVG Volume (30 Days)
- OLO 6.5M
- COGT 4.8M
- Earning Date
- OLO 08-04-2025
- COGT 08-05-2025
- Dividend Yield
- OLO N/A
- COGT N/A
- EPS Growth
- OLO N/A
- COGT N/A
- EPS
- OLO 0.01
- COGT N/A
- Revenue
- OLO $299,107,000.00
- COGT N/A
- Revenue This Year
- OLO $20.21
- COGT N/A
- Revenue Next Year
- OLO $17.90
- COGT N/A
- P/E Ratio
- OLO $979.26
- COGT N/A
- Revenue Growth
- OLO 23.31
- COGT N/A
- 52 Week Low
- OLO $4.56
- COGT $3.72
- 52 Week High
- OLO $10.55
- COGT $12.97
- Technical
- Relative Strength Index (RSI)
- OLO 81.66
- COGT 64.59
- Support Level
- OLO $10.12
- COGT $11.84
- Resistance Level
- OLO $10.55
- COGT $12.28
- Average True Range (ATR)
- OLO 0.04
- COGT 0.59
- MACD
- OLO -0.02
- COGT -0.21
- Stochastic Oscillator
- OLO 84.71
- COGT 33.19
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.